Difficult-to-treat depressionChallenges in the treatment of depression with psychotic features
Introduction
Major depression with psychotic features (MDpsy), a disorder with considerable morbidity and mortality, is more common than is generally realized and is encountered frequently in clinical practice. In a study of consecutively admitted patients hospitalized for major depression, Coryell et al (1984) reported that 25% of the patients met criteria for MDpsy. In the Epidemiologic Catchment Area Study (Johnson et al 1991), 14.7% of patients who met criteria for major depression had a history of psychotic features. Although the prevalence may be as high as 45% in samples of elderly patients with major depression (Meyers and Greenberg 1986), MDpsy is not limited to older people and can occur in younger people as well. Unfortunately, MDpsy is often not diagnosed accurately because the psychosis may be subtle, intermittent, or concealed, leading to a misdiagnosis of nonpsychotic depression.
There has been a long-standing debate as to whether MDpsy is a distinct syndrome or merely represents a more severe depressive subtype (reviewed in Schatzberg and Rothschild 1996); however, in several studies, severity alone did not account for differences between MDpsy and nonpsychotic depression on measures of symptoms (Coryell et al 1984), hypothalamic–pituitary–adrenal (HPA) axis activity (Brown et al 1988), sleep (Thase et al 1986a), and treatment response Chan et al 1987, Glassman et al 1977. Other studies that have controlled for the presence of endogenous features have also observed that the differences between MDpsy and nonpsychotic depression are not simply due to differences in endogenicity. This includes studies of differentiating symptoms (Parker et al 1991), HPA axis activity Brown et al 1988, Evans et al 1983, Rihmer et al 1984, and treatment response Avery and Lubrano 1979, Chan et al 1987.
The systematic study of MDpsy has been limited by several factors: 1) the fact that the disorder does not exist as a distinct diagnostic subtype in the DSM-IV American Psychiatric Association Committee on Nomenclature and Statistics 1994, Schatzberg and Rothschild 1992; 2) very few psychiatric researchers have made the study of MDpsy a priority; 3) difficulties in enrolling patients with this disorder in research studies; and 4) the fact that the diagnosis is often missed by clinicians.
The degree of morbidity and mortality seen among patients with psychotic depression underscores the importance of intelligent and empirically guided treatment decisions, but the nature of the illness itself makes controlled treatment studies extremely difficult to execute. As a result, there have been very few controlled studies regarding the acute treatment of psychotic depression and no long-term maintenance treatment studies.
The purpose of this article is to review our current understanding of the treatment of major depression with psychotic features. First, the difficulties in accurately diagnosing MDpsy will be discussed. Next, there will be a brief review of the studies of family history, course, and biology of MDpsy. This is followed by a discussion of the possible relationship between MDpsy and bipolar disorder. The remainder of the paper is devoted to the treatment of MDpsy and is divided into sections by treatment modality: tricyclic antidepressants (TCAs), electroconvulsive therapy (ECT), combined antidepressant/antipsychotic treatment, studies with selective serotonin reuptake inhibitors (SSRIs), lithium augmentation, the role of atypical antipsychotics, hypercortisolemia and antiglucocorticoid strategies, and treatment guidelines.
Section snippets
Diagnosis
According to DSM-IV criteria (American Psychiatric Association Committee on Nomenclature and Statistics 1994), one cannot make the diagnosis of MDpsy unless one can detect the presence of delusions or hallucinations in the context of a major depressive episode; however, because the detection of delusions and hallucinations is often difficult in patients with MDpsy (Rothschild and Schatzberg 1993), a number of research groups have explored whether there are other characteristics that may help
Family history
In some studies, the first-degree relatives of patients with MDpsy exhibit higher rates of depression Leckman et al 1984, Nelson et al 1984 and the psychotic subtype (Leckman et al 1984) than do the family members of patients with nonpsychotic depression, although not all studies are in agreement Bond et al 1986, Coryell et al 1982, Coryell et al 1984, Frangos et al 1983; Maj et al 1991, Price et al 1984. In one study (Bond et al 1986), when the MDpsy group was divided by degree of HPA axis
Course
Patients with MDpsy exhibit more frequent relapses or recurrences than patients with nonpsychotic depression Aronson et al 1987, Aronson et al 1988a, Aronson et al 1988b, Baldwin and Jolley 1986, Coryell et al 1996, Helms and Smith 1983, Lykouras et al 1986, Murphy 1983, Nelson and Bowers 1978, Robinson and Spiker 1985, Rothschild et al 1993b; Spiker et al 1985); although not all studies are in agreement Coryell et al 1987, Lykouras et al 1994. Patients with MDpsy (when compared with
Biology
There exists considerable evidence from studies of the HPA axis, studies of dopaminergic activity, enzyme studies, brain imaging, electroencephalographic sleep profiles, and measures of serotonergic function that points to distinct biological abnormalities in MDpsy as compared with nonpsychotic depression. Details of these biological studies are summarized elsewhere (Schatzberg and Rothschild 1992). For example, several groups have reported specific abnormalities in HPA axis activity of
Relationship to bipolar disorder
Several studies support a relationship between MDpsy and bipolar disorder. Strober and Carlson (1982) observed 60 adolescents hospitalized with unipolar major depression. They reported a 20% conversion rate to bipolar disorder, predicted in part by a depressive symptom cluster consisting of mood-congruent psychotic features (75% of converters vs. 6% of nonconverters, p < .001), psychomotor retardation, and rapid symptom onset. Similarly, Akiskal et al (1983) observed a 20% conversion rate to
Tricyclic antidepressants
When the TCAs were introduced for the treatment of depression, reports began to appear that they were not as effective for MDpsy as in depression in general Angst 1961, Friedman et al 1961, Hordern et al 1963. One example of this is the landmark DeCarolis study (Avery and Lubrano 1979), which observed a 40% response rate in MDpsy patients treated with 200–350 mg/day of imipramine for at least 25 days. Those patients who did not respond to the imipramine then received ECT; for these patients the
Conclusions
In summary, MDpsy is associated with significant morbidity and mortality. Currently, the most effective treatments include the combination of an antidepressant with an antipsychotic, or ECT. Recent studies suggest that atypical antipsychotic medications may be effective (when combined with an antidepressant) for the acute treatment of MDpsy; however, there remain many questions for future research. Those that seem of greatest importance include the following: 1) the efficacy and safety of
Acknowledgements
Supported in part by the Irving S. and Betty Brudnick Endowed Chair in Psychiatry, University of Massachusetts Medical School.
Aspects of this work were presented at the conference, “Difficult-to- Treat Depression” held April 21–22, 2002 in San Francisco, California. The conference was sponsored by the Society of Biological Psychiatry through an unrestricted grant provided by Eli Lilly and Company.
References (132)
- et al.
Bipolar outcome in the course of depressive illnessPhenomenological, familial, and pharmacologic predictors
J Affect Disord
(1983) - et al.
Antiglucocorticoid treatment of refractorydepression with ketoconazoleA case report
Biol Psychiatry
(1995) Urinary free cortisol in psychotic depression
Biol Psychiatry
(1987)- et al.
Relapse in delusional depressionA retrospective study of the course of treatment
Comp Psychiatry
(1988) - et al.
Proposed delusional depression subtypesPreliminary evidence from a retrospective study of phenomenology and treatment course
J Affect Disord
(1988) - et al.
Delusional depression, family history, and DST responseA pilot study
Biol Psychiatry
(1986) - et al.
Psychotic features in major depressionIs mood congruence important?
J Affect Disord
(1982) - et al.
Elevated homovanillic acid in depressed females with melancholia and psychosis
Psychiatry Res
(1985) - et al.
Psychotic depressive disorderA separate entity?
J Affect Dis
(1983) - et al.
Recurrent psychotic depressionEvidence of diagnostic stability
J Affect Disord
(1983)
Plasma catecholamine metabolites in subtypes of major depression
Biol Psychiatry
Late-life delusional depression
J Affect Disord
Serum DBH activity in psychotic vs. nonpsychotic unipolar and bipolar depression
Psychiatry Res
Delusional depressionPhenomenology, neuroendocrine function, and tricyclic antidepressant response
J Affect Disord
Electroconvulsive therapy in delusional and nondelusional depressive disorder
J Affect Disord
Distinguishing psychotic and non-psychotic melancholia
J Affect Disord
Psychotic (delusional) depressionA meta-analysis of physical treatments
J Affect Disord
Family history in delusional depression
J Affect Disord
Delusional depressionA one year follow-up
J Affect Disord
Management of psychotic, treatment-resistant depression
Psychiatr Clin North Am
Higher CSF levels of HVA and 5-HIAA in delusional compared to non delusional depression
Arch Gen Psychiatry
Diagnostic and Statistical Manual of Mental Disorders
Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole
A clinical analysis of the effects of Tofranil in depression
Psychopharmacologia
Amoxapine versus amitriptyline combined with (208) perphenazine in the treatment of psychotic depression
Am J Psychiatry
Efficacy of amoxapine in psychotic depression
Am J Psychiatry
Continuation therapy after ECT for delusional depressionA naturalistic study of prophylactic treatments and relapse
Convuls Ther
Depression treated with imipramine and ECTThe DeCarolis study reconsidered
Am J Psychiatry
The prognosis of depression in old age
Br J Psychiatry
Clozapine therapy in refractory affective disordersPolarity predicts response in long-term follow-up
J Clin Psychiatry
Neuropsychological deficits in psychotic versus nonpsychotic unipolar depression
Neuropsychology
Lithium augmentation in treatment-resistant depressionMeta-analysis of placebo-controlled trials
J Clin Psychopharmacol
Rapid reversal of psychotic major depression using mifepristone
J Clin Psychopharmacol
Cortisol activity and cognitive changes in psychotic major depression
Am J Psychiatry
Adrenocortical hyperactivity in depressionEffects of agitation, delusions, melancholia, and other illness variables
Psychiatry Res
Clozapine use in diffuse Lewy body disease
J Neuropsychiatry Clin Neurosci
Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants
J Clin Psychiatry
The importance of psychotic features to major depressionCourse and outcome during a 2-year follow-up
Acta Psychiatr Scand
Affective syndromes, psychotic features and prognosis IDepression
Arch Gen Psychiatry
The importance of psychotic features to long term course in depressive disorders
Am J Psychiatry
The clinical and neuroendocrine features of psychotic depression
J Nerv Ment Dis
Primary unipolar depression and the prognostic importance of delusions
Arch Gen Psychiatry
Demographic, historical, and symptomatic features of the nonmanic psychoses
J Nerv Ment Dis
Outcome at discharge and six months in major depression. The significance of psychotic features
J Nerv Ment Dis
Clozapine in the treatment of psychotic refractory depression
Br J Psychiatry
Treatment of psychotic depression
Am J Psychiatry
Cited by (93)
Guidelines for the management of psychosis in the context of mood disorders
2022, Schizophrenia ResearchCognitive markers of psychotic unipolar depression: A meta-analytic study
2015, Journal of Affective DisordersCitation Excerpt :In the DSM-5 (A.P.A., 2013), though being still included among the severity/course specifiers, the specifier “with psychotic features” is permitted for both bipolar and depressive disorder in connection with any depressive episode regardless of its severity. Furthermore, several biological markers, such as the presence of enlarged cerebral ventricles and paralimbic abnormalities (Keller et al., 2007; Lykouras and Gournellis, 2009; Rothschild, 2003), or a decrease in serum dopamine-beta-hydroxylase activity (Keller et al., 2007; Lykouras and Gournellis, 2009; Rothschild, 2003), seem to place MDDP as a separate disease entity, having its own clinical presentation and illness course (Østergaard et al., 2012, 2014; Park et al., 2014). A previous meta-analytic study on MDDP reported that patients with psychotic symptoms are cognitively more impaired than non-psychotic depressed subjects (Fleming et al., 2004).
Meta-review of depressive subtyping models
2012, Journal of Affective DisordersCitation Excerpt :Similar to melancholia, core biological correlates are hypercortisolemia and reduced REM latency (Keller et al., 2007a; Lykouras and Gournellis, 2009; Rothschild, 2003). In relation to healthy control subjects, a decrease in serum dopamine-beta-hydroxylase activity (the enzyme that converts dopamine to norepinephrine) compared to an increased activity in non-psychotic depressed patients was shown (Keller et al., 2007a; Lykouras and Gournellis, 2009; Rothschild, 2003). Moreover, enlarged cerebral ventricles and paralimbic abnormalities have been reported (Keller et al., 2007a; Lykouras and Gournellis, 2009; Rothschild, 2003).
Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features
2011, Journal of Affective Disorders